EP 225: Lessons from 20 years of building ocular gene therapies with Daniel Chung of Beacon Tx

EP 225: Lessons from 20 years of building ocular gene therapies with Daniel Chung of Beacon Tx

by Sano Genetics

Life & Natural Systems Medicine & Health MKZTherapy and therapeuticsMKZVGene therapy
🎙 Sano Genetics 👥 942 📅 February 5, 2026 ⏱ 39 min 👁 78 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

gene therapyocularclinical trialsendpointsAAV

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Dr. Daniel Chung, Chief Medical Officer of Beacon Therapeutics, about his extensive experience in developing ocular gene therapies. Chung discusses his involvement in the development and approval of Luxturna, the first in vivo gene therapy for a genetic disease, targeting RPE65-mediated inherited retinal dystrophy. He explains the challenges and successes of that pioneering work, including the development of the novel MLMT endpoint. The conversation then shifts to the current state of the field, noting that despite Luxturna’s approval in 2017, no other ocular gene therapy has been approved since, though several are in late-stage trials. Chung provides an overview of ocular diseases suitable for gene therapy, distinguishing between rare monogenic conditions and more common diseases like wet AMD and geographic atrophy. He details the complexities of designing pivotal trials for X-linked retinitis pigmentosa (XLRP), emphasizing the importance of selecting appropriate clinical endpoints that satisfy regulators and payers. He shares lessons from two previously failed RPGR trials, highlighting the need for robust endpoints like low luminance visual acuity and mean microperimetry. Chung also discusses the challenges of AAV packaging constraints, immunogenicity, and the importance of surgical delivery standardization. He touches on the potential for expanding treatment to earlier-stage patients and other indications, including geographic atrophy. Finally, he addresses the broader scientific, regulatory, and commercial challenges facing gene therapy today, including access to genetic testing and the need for positive clinical data to attract investment.

244 words

Critical Evaluation

Value of the Information & Strength of the Argument

The podcast provides valuable insights from a leading expert in ocular gene therapy, offering a comprehensive overview of the field’s history, current challenges, and future directions. Chung’s arguments are well-supported by his direct experience with Luxturna and his current role at Beacon Therapeutics. He provides specific examples of trial design issues, such as the selection of endpoints and the importance of regulatory and payer perspectives. The discussion is balanced, acknowledging both successes and failures, and offers practical lessons for researchers and clinicians. The argumentation is solid, though it relies on anecdotal evidence and personal experience rather than formal data or citations.

Scientific Rigor, Source Quality, Title Accuracy

The podcast demonstrates high scientific rigor in its discussion of clinical trial design and regulatory pathways, reflecting the expertise of the guest. However, it lacks formal citations or references to specific studies, relying instead on the speaker’s experience. The title accurately represents the content, which focuses on lessons from two decades of ocular gene therapy development. The show notes provide a clear outline, and the description includes a link to Beacon Therapeutics’ website, but no additional sources are cited. The discussion is credible but would benefit from references to published literature for verification.

209 words

Title / Content Match

The title accurately reflects the content, which focuses on lessons from two decades of ocular gene therapy development, as discussed by Daniel Chung.

Quality & Reliability

8/10

The podcast features an expert with over 30 years of experience in ophthalmology and gene therapy, providing detailed insights into clinical trial design, regulatory pathways, and commercial considerations. The discussion is grounded in real-world experience, including the development of Luxturna. However, it is an opinion-based conversation without formal citations or peer-reviewed references, and some claims are not independently verifiable.

Chapters

Cited Sources

  • Beacon Therapeutics — Mentioned as the company where Daniel Chung serves as Chief Medical Officer.
  • Show Notes — Provided in the description for further information about the episode.

Concurring Sources

  • Beacon Therapeutics — Official website of the company, providing information on their pipeline and programs.

Contribution & Novelties

This podcast offers a unique perspective from a key figure in the development of the first approved ocular gene therapy, providing valuable lessons for the field. Chung’s insights into endpoint selection, trial design, and regulatory interactions are particularly informative. The discussion of the challenges and potential solutions for XLRP trials adds practical knowledge for researchers.

Pour aller plus loin :

  • Gene therapy for inherited retinal diseases — Provides background on the topic.
  • Luxturna (voretigene neparvovec) — Details on the first approved gene therapy.
  • Adeno-associated virus (AAV) — Explains the vector used in many gene therapies.
  • Inherited retinal dystrophy — Overview of the disease category.

104 words

Radar Profile

The radar profile shows high scores in information quantity and quality, reflecting the expert's detailed insights. The technical level is moderately high, suitable for a professional audience. Reliability is strong due to the speaker's experience, though the lack of formal citations slightly reduces the score.

Reliability 7/10